ShareValue scores for 688755.SHG: Valuation 56, Quality 61, Growth 56, Health 80.
688755.SHGSSE
Jiangsu Hanbon Science and Technology Co., Ltd.
CN¥23.81
(-4.22%)
Updated
688755.SHGSSE
Jiangsu Hanbon Science and Technology Co., Ltd.
Updated
Pulse
Pulse
Fundamental Rating
Value Trap Risk
If P/E met sector median
Rating
Trap Risk
P/E to median
vs Shanghai-listed Healthcare stocks
Company Details
Jiangsu Hanbon Science and Technology Co., Ltd. engages in the research and development, production, and sale of liquid chromatography products in China and internationally. It offers biopharm purification equipment, including chromatography column products, chromatography systems, buffer dilution/conditioning systems, filtration systems, and single-use systems; bio-oligo synthesizer products, such as nucleic acid synthesizer and oligonucleotide synthesis column products; and preparative liquid chromatography system and chromatographic column products. It also provides continuous chromatographic systems comprising simulated moving bed and continuous Ion exchange chromatography products; and supercritical fluid chromatography products, including analytical supercritical fluid chromatography, SFC-dynamic axial compression column, and CO2 booster station products. In addition, it offers biopharmaceutical purification, peptide purification, and small molecule purification solutions. The company was founded in 1998 and is based in Huai'an, China.
Score Analysis
AI Investment Thesis
Jiangsu Hanbon Science and Technology Co., Ltd. is fairly valued versus Shanghai-listed Healthcare stocks: P/S of 3.15 is lower than 70% of peers, though P/E of 34.9 is higher than 52%.
Quality is the standout: a 10.2% net margin and 6.96% ROE contrast with the sector's loss-making average, and nine-month operating cash flow rose 92% to CN¥111 million.
The 30 October third-quarter report showed revenue up 22.5% to CN¥620 million and net profit up 72.9% to CN¥64 million, with third-quarter profit up 112.5%.